PURPOSE: Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome. Their prognostic significance in adult T-ALL is unclear. We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol. METHODS: NOTCH1 and FBXW7 were screened by a combination of denaturing high-performance liquid chromatography and sequencing in 88 adult patients with T-ALL treated on the UKALLXII/ECOG E2993 protocol and compared with clinical characteristics and outcome. RESULTS: NOTCH1 and FBXW7 mutations were common (60% and 18%, respectively) and were not associated with age or WBC count. NOTCH1 heterodimerization domain mutations were associated with FBXW7 mutations (P = .02), and NOTCH1 proline, glutamic acid, serine, threonine (PEST) rich domain and FBXW7 mutations were mutually exclusive. There were an equal number of high- and standard-risk patients in the NOTCH1 and FBXW7 mutated (MUT) groups. Patients wild type (WT) for both markers trended toward poorer event-free survival (EFS; MUT v WT, 51% v 27%, P = .10; hazard ratio, 0.6). Analysis by each marker individually was not significantly predictive of outcome (NOTCH1 MUT v WT, EFS 49% v 34%, P = .20; FBXW7 MUT v WT, EFS 53% v 41%, P.72). CONCLUSION: NOTCH1 and FBXW7 mutant-positive patients do not fare sufficiently well to warrant an individualized treatment approach in future studies.
PURPOSE:Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome. Their prognostic significance in adult T-ALL is unclear. We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol. METHODS:NOTCH1 and FBXW7 were screened by a combination of denaturing high-performance liquid chromatography and sequencing in 88 adult patients with T-ALL treated on the UKALLXII/ECOG E2993 protocol and compared with clinical characteristics and outcome. RESULTS:NOTCH1 and FBXW7 mutations were common (60% and 18%, respectively) and were not associated with age or WBC count. NOTCH1 heterodimerization domain mutations were associated with FBXW7 mutations (P = .02), and NOTCH1proline, glutamic acid, serine, threonine (PEST) rich domain and FBXW7 mutations were mutually exclusive. There were an equal number of high- and standard-risk patients in the NOTCH1 and FBXW7 mutated (MUT) groups. Patients wild type (WT) for both markers trended toward poorer event-free survival (EFS; MUT v WT, 51% v 27%, P = .10; hazard ratio, 0.6). Analysis by each marker individually was not significantly predictive of outcome (NOTCH1 MUT v WT, EFS 49% v 34%, P = .20; FBXW7 MUT v WT, EFS 53% v 41%, P.72). CONCLUSION:NOTCH1 and FBXW7 mutant-positive patients do not fare sufficiently well to warrant an individualized treatment approach in future studies.
Authors: Teresa Palomero; Wei Keat Lim; Duncan T Odom; Maria Luisa Sulis; Pedro J Real; Adam Margolin; Kelly C Barnes; Jennifer O'Neil; Donna Neuberg; Andrew P Weng; Jon C Aster; Francois Sigaux; Jean Soulier; A Thomas Look; Richard A Young; Andrea Califano; Adolfo A Ferrando Journal: Proc Natl Acad Sci U S A Date: 2006-11-17 Impact factor: 11.205
Authors: Andrew P Weng; John M Millholland; Yumi Yashiro-Ohtani; Marie Laure Arcangeli; Arthur Lau; Carol Wai; Cristina Del Bianco; Carlos G Rodriguez; Hong Sai; John Tobias; Yueming Li; Michael S Wolfe; Cathy Shachaf; Dean Felsher; Stephen C Blacklow; Warren S Pear; Jon C Aster Journal: Genes Dev Date: 2006-07-17 Impact factor: 11.361
Authors: Stephen Breit; Martin Stanulla; Thomas Flohr; Martin Schrappe; Wolf-Dieter Ludwig; Gabriele Tolle; Margit Happich; Martina U Muckenthaler; Andreas E Kulozik Journal: Blood Date: 2006-04-13 Impact factor: 22.113
Authors: Alena Malyukova; Takeaki Dohda; Natalie von der Lehr; Shahab Akhoondi; Shahab Akhondi; Martin Corcoran; Mats Heyman; Charles Spruck; Dan Grandér; Urban Lendahl; Olle Sangfelt Journal: Cancer Res Date: 2007-06-15 Impact factor: 12.701
Authors: Jacob M Rowe; Georgina Buck; Alan K Burnett; Raj Chopra; Peter H Wiernik; Susan M Richards; Hillard M Lazarus; Ian M Franklin; Mark R Litzow; Niculae Ciobanu; H Grant Prentice; Jill Durrant; Martin S Tallman; Anthony H Goldstone Journal: Blood Date: 2005-08-16 Impact factor: 22.113
Authors: Anthony V Moorman; Christine J Harrison; Georgina A N Buck; Sue M Richards; Lorna M Secker-Walker; Mary Martineau; Gail H Vance; Athena M Cherry; Rodney R Higgins; Adele K Fielding; Letizia Foroni; Elisabeth Paietta; Martin S Tallman; Mark R Litzow; Peter H Wiernik; Jacob M Rowe; Anthony H Goldstone; Gordon W Dewald Journal: Blood Date: 2006-12-14 Impact factor: 22.113